2.26
Collplant Biotechnologies Ltd stock is traded at $2.26, with a volume of 40,601.
It is down -4.64% in the last 24 hours and down -9.29% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$2.37
Open:
$2.45
24h Volume:
40,601
Relative Volume:
0.40
Market Cap:
$28.74M
Revenue:
$2.47M
Net Income/Loss:
$-13.87M
P/E Ratio:
-1.8525
EPS:
-1.22
Net Cash Flow:
$-12.42M
1W Performance:
-5.83%
1M Performance:
-9.29%
6M Performance:
+1.80%
1Y Performance:
-42.05%
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CLGN
Collplant Biotechnologies Ltd
|
2.26 | 30.14M | 2.47M | -13.87M | -12.42M | -1.22 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
584.74 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
814.17 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.54 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
What momentum shifts mean for CollPlant Biotechnologies Ltd.Quarterly Earnings Report & Weekly Consistent Profit Watchlists - newser.com
Signal strength of CollPlant Biotechnologies Ltd. stock in tech scannersWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Is CollPlant Biotechnologies Ltd. stock dividend yield sustainableTrade Volume Report & AI Driven Stock Reports - newser.com
How CollPlant Biotechnologies Ltd. (CPT) stock performs in easing cyclesWeekly Gains Report & Daily Oversold Bounce Ideas - newser.com
Applying sector rotation models to CollPlant Biotechnologies Ltd.Analyst Downgrade & Reliable Price Action Trade Plans - newser.com
Pattern recognition hints at CollPlant Biotechnologies Ltd. upsideWeekly Trading Summary & Pattern Based Trade Signal System - newser.com
Can swing trading help recover from CollPlant Biotechnologies Ltd. lossesQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Will CollPlant Biotechnologies Ltd. (CPT) stock benefit from commodity supercycle2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Published on: 2025-10-21 10:44:31 - newser.com
Historical volatility pattern of CollPlant Biotechnologies Ltd. visualizedJuly 2025 Gainers & Technical Entry and Exit Tips - newser.com
Is CollPlant Biotechnologies Ltd. forming a bottoming baseWeekly Market Report & Safe Entry Point Alerts - newser.com
CollPlant Biotechnologies (NASDAQ:CLGN) Given Buy Rating at D. Boral Capital - Defense World
What technical patterns form on CollPlant Biotechnologies Ltd. (CPT) stock charts2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Predicting CollPlant Biotechnologies Ltd. trend using moving averagesQuarterly Portfolio Summary & AI Based Buy and Sell Signals - newser.com
Strategies to average down on CollPlant Biotechnologies Ltd.2025 Retail Activity & Real-Time Volume Triggers - newser.com
D. Boral Capital Maintains CollPlant Biotechnologies (CLGN) Buy Recommendation - Nasdaq
CLGN: Analyst Jason Kolbert Maintains Buy Rating with $12.00 Pri - GuruFocus
CollPlant’s bioink outperforms Matrigel in tissue formation study By Investing.com - Investing.com Australia
2025-10-20 | CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by TechnionIsrael Institute of Technology | NDAQ:CLGN | Press Release - Stockhouse
Will CollPlant Biotechnologies Ltd. stock outperform Nasdaq indexJuly 2025 Retail & Risk Controlled Stock Pick Alerts - newser.com
Will CollPlant Biotechnologies Ltd. stock benefit from commodity prices2025 Volume Leaders & Safe Capital Investment Plans - nchmf.gov.vn
Will CollPlant Biotechnologies Ltd. stock outperform Dow Jones index2025 Market Sentiment & Community Consensus Stock Picks - nchmf.gov.vn
Can CollPlant Biotechnologies Ltd. stock beat market expectations this quarterEarnings Risk Report & Smart Money Movement Tracker - nchmf.gov.vn
How CollPlant Biotechnologies Ltd. stock reacts to Fed rate cuts2025 Market Trends & Weekly High Conviction Ideas - nchmf.gov.vn
Revenue Check: Why CollPlant Biotechnologies Ltd. stock is trending among retail tradersOptions Play & Momentum Based Trading Signals - nchmf.gov.vn
CollPlant Biotechnologies shares slide after announces capital raise of $3.6M through registered direct offering - MSN
How CollPlant Biotechnologies Ltd. stock benefits from tech adoptionJuly 2025 Sector Moves & Risk Managed Trade Strategies - newser.com
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):